Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cpg-52852. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 known ✓ | Q9NYK1 | 20/20 | 1.00 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cpg-52852 SCHEMBL483385 | 1.00 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL29182347 | 0.97 | TLR7 (0.94) | TLR7TLR8 | |
| SCHEMBL18429392 | 0.93 | TLR7 (0.86) | TLR7TLR8 | |
| SCHEMBL483689 | 0.92 | TLR7 (0.85) | TLR7TLR8 | |
| SCHEMBL29852269 | 0.92 | TLR7 (0.85) | TLR7TLR8 | |
| SCHEMBL18680036 | 0.92 | TLR7 (0.85) | TLR7TLR8 | |
| SCHEMBL728467 | 0.91 | TLR7 (0.84) | TLR7TLR8 | |
| SCHEMBL2744306 | 0.91 | TLR7 (0.83) | TLR7TLR8 | |
| SCHEMBL3973102 | 0.90 | TLR7 (0.82) | TLR7TLR8 | |
| SCHEMBL3975772 | 0.90 | TLR7 (0.82) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | claimed |
| EP-3763742-B1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-10-05 | — | — | EP | claimed |
| CN-114716555-A | Compounds and compositions for targeting EGFR expressing tumors | 博笛生物科技有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114671954-A | Compounds and compositions targeting HER2 positive tumors | 博笛生物科技有限公司 | 2022-06-28 | — | — | CN | claimed |
| EP-3980080-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | Sutro Biopharma, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| CN-114206392-A | Immunomodulatory agent antibody drug conjugates and uses thereof | 苏特罗生物制药公司 | 2022-03-18 | — | — | CN | claimed |
| WO-2022047279-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC (US) | 2022-03-03 | — | — | WO | claimed |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260109747-A1 | Conjugate Comprising an IL-2 Moiety | ASCENDIS PHARMA ONCOLOGY DIV A/S (DK) | 2026-04-23 | — | — | US | disclosed |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| EP-4709423-A1 | NOVEL CANCER TREATMENTS WITH IL-2 CONJUGATES | Ascendis Pharma Oncology Division A/S (DK) | 2026-03-18 | — | — | EP | disclosed |
| EP-4705284-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260049145-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2026-02-19 | — | — | US | disclosed |
| WO-2022047279-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | Ascendis Pharma Oncology Division A/S (DK) | 2022-03-03 | — | — | US | disclosed |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| US-20220054478-A1 | MINIMIZATION OF SYSTEMIC INFLAMMATION | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| US-20220054476-A1 | SUSTAINED LOCAL DRUG LEVELS FOR INNATE IMMUNE AGONISTS | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| EP-3166976-B1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-02-23 | — | — | EP | disclosed |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054478-A1 | MINIMIZATION OF SYSTEMIC INFLAMMATION | CCR10, CXCL10, PROKR1 | TLR7 91/4885TLR8 85/4885 |
| US-20260109747-A1 | Conjugate Comprising an IL-2 Moiety | IL2, IL2RA, ILF2 | TLR7 1753/4885TLR8 1312/4885 |
| US-20220054476-A1 | SUSTAINED LOCAL DRUG LEVELS FOR INNATE IMMUNE AGONISTS | TLR3, TLR1, TLR9 | TLR7 4/4885TLR8 7/4885 |
| US-20260049145-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | PDCD1, PDCD1LG2, CD274 | TLR7 57/4885TLR8 90/4885 |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | CD274, PDCD1LG2, PDCD1 | TLR7 883/4885TLR8 671/4885 |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | GRPR, TLR3, TLR1 | TLR7 9/4885TLR8 7/4885 |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | TLR7 2107/4885TLR8 2251/4885 |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NSUN2, SARS1, SNRPE | TLR7 76/4885TLR8 300/4885 |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | TLR7 210/4885TLR8 87/4885 |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | LPAR1, TACR1, ADGRF1 | TLR7 57/4885TLR8 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.